Adaptimmune Therapeutics plc, of Oxford, U.K., said the EMA Committee for Orphan Medicinal Products has adopted a positive opinion recommending their T-cell therapy targeting NY-ESO for designation as an orphan medicinal product for the treatment of soft tissue sarcoma.